Health Catalyst, Inc. (NASDAQ:HCAT) Stock Rated "Reduce" by Wall Street Brokerages

Health Catalyst logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Analysts have a “Reduce” consensus on Health Catalyst: five of six covering analysts rate it Hold and one rates it Sell. The average one-year price target is $2.01, with several firms recently lowering their targets.
  • In its latest reported quarter, Health Catalyst posted a loss of $0.03 per share, beating estimates for a $0.05 loss, and revenue of $56.28 million, above the $55.39 million consensus.
  • The stock opened at $1.29 and has traded between $0.96 and $3.02 over the past year. Insider activity was mixed: the CEO bought 59,000 shares, while the general counsel sold 29,478 shares.
  • Five stocks to consider instead of Health Catalyst.

Shares of Health Catalyst, Inc. (NASDAQ:HCAT - Get Free Report) have been given a consensus recommendation of "Reduce" by the six analysts that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation and five have given a hold recommendation to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $2.01.

A number of research firms have commented on HCAT. Citigroup reduced their price objective on Health Catalyst from $2.50 to $2.00 and set a "neutral" rating on the stock in a research note on Tuesday, August 11th. Weiss Ratings restated a "sell (d-)" rating on shares of Health Catalyst in a research note on Monday, October 26th. Canaccord Genuity Group lowered Health Catalyst from a "buy" rating to a "hold" rating and lowered their target price for the company from $3.00 to $1.80 in a research note on Thursday, August 20th. Finally, Wells Fargo & Company cut their price target on Health Catalyst from $1.75 to $1.50 and set an "equal weight" rating for the company in a report on Thursday, August 13th.

Get Our Latest Report on Health Catalyst

Health Catalyst Stock Performance

NASDAQ:HCAT opened at $1.29 on Friday. The stock has a market capitalization of $98.23 million, a P/E ratio of -0.46 and a beta of 1.52. Health Catalyst has a 1 year low of $0.96 and a 1 year high of $3.02. The firm has a 50 day moving average of $1.66 and a 200-day moving average of $1.67.

Health Catalyst (NASDAQ:HCAT - Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The company reported ($0.03) EPS for the quarter, topping analysts' consensus estimates of ($0.05) by $0.02. Health Catalyst had a negative return on equity of 4.84% and a negative net margin of 74.24%. The business had revenue of $56.28 million for the quarter, compared to analyst estimates of $55.39 million. As a group, analysts forecast that Health Catalyst will post -0.22 EPS for the current fiscal year.

Insider Transactions at Health Catalyst

In other Health Catalyst news, General Counsel Benjamin Landry sold 29,478 shares of the firm's stock in a transaction dated Thursday, November 12th. The shares were sold at an average price of $1.39, for a total value of $40,974.42. Following the completion of the sale, the general counsel owned 251,894 shares in the company, valued at approximately $350,132.66. This trade represents a 10.48% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Simeon Kohl bought 59,000 shares of the company's stock in a transaction on Monday, September 14th. The stock was bought at an average cost of $1.79 per share, with a total value of $105,610.00. Following the completion of the purchase, the chief executive officer owned 2,856,385 shares of the company's stock, valued at approximately $5,112,929.15. The trade was a 2.11% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. 19.40% of the stock is owned by corporate insiders.

Institutional Trading of Health Catalyst

A number of hedge funds and other institutional investors have recently modified their holdings of HCAT. Palogic Value Management L.P. acquired a new position in Health Catalyst during the 2nd quarter worth $9,796,000. BlackRock Inc. acquired a new stake in shares of Health Catalyst in the 2nd quarter valued at $3,654,000. Marshall Wace LLP acquired a new stake in shares of Health Catalyst in the 3rd quarter valued at $1,810,000. Mink Brook Asset Management LLC increased its stake in shares of Health Catalyst by 25.4% in the 3rd quarter. Mink Brook Asset Management LLC now owns 925,510 shares of the company's stock valued at $1,601,000 after buying an additional 187,233 shares during the period. Finally, Hsbc Holdings PLC acquired a new stake in shares of Health Catalyst in the 2nd quarter valued at $809,000. Institutional investors and hedge funds own 85.00% of the company's stock.

Health Catalyst Company Profile

(Get Free Report)

Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations. Its solutions are designed to help providers use clinical, operational, and financial data to support decision-making and improve care delivery. The company's offerings include a data platform that brings together information from multiple sources, analytics applications for healthcare workflows, and professional services. These services can include implementation, data management, and support for organizations developing and applying analytics programs.

Recommended Stories

Analyst Recommendations for Health Catalyst (NASDAQ:HCAT)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Health Catalyst Right Now?

Before you consider Health Catalyst, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Health Catalyst wasn't on the list.

While Health Catalyst currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines